Ekso Bionics (NASDAQ:EKSO) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research report report published on Wednesday morning. The firm issued a hold rating on the stock.

Other equities research analysts have also issued research reports about the stock. HC Wainwright restated a “buy” rating and issued a $9.00 target price on shares of Ekso Bionics in a report on Tuesday, March 4th. Lake Street Capital dropped their target price on Ekso Bionics from $2.00 to $1.00 and set a “buy” rating for the company in a research report on Tuesday, March 4th.

Ekso Bionics Trading Up 4.4 %

Shares of NASDAQ EKSO opened at $0.45 on Wednesday. Ekso Bionics has a 1-year low of $0.34 and a 1-year high of $1.53. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.81 and a quick ratio of 2.14. The business’s 50 day moving average is $0.55 and its two-hundred day moving average is $0.77. The stock has a market capitalization of $11.15 million, a P/E ratio of -0.69 and a beta of 1.43.

Ekso Bionics (NASDAQ:EKSO) last announced its earnings results on Monday, March 3rd. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.07). Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. The company had revenue of $5.09 million during the quarter, compared to analysts’ expectations of $5.05 million. As a group, research analysts expect that Ekso Bionics will post -0.48 EPS for the current year.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.